Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Jiangxi Rimag Group Co., Ltd. Class H ( (HK:2522) ) is now available.
Jiangxi Rimag Group Co., Ltd. has announced the acquisition of a 70% equity interest in Gaomai Health, a company engaged in nuclear medical imaging technology. This acquisition will make Gaomai Health a subsidiary of Jiangxi Rimag, allowing the company to consolidate its financial results. The strategic move aims to enhance Jiangxi Rimag’s capabilities in nuclear medicine projects and promote innovative business models and technologies in the third-party medical imaging services industry. The collaboration with Gaomai Health is expected to leverage both companies’ expertise to explore new opportunities and improve precision diagnosis capabilities in nuclear medicine.
The most recent analyst rating on (HK:2522) stock is a Buy with a HK$21.41 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
More about Jiangxi Rimag Group Co., Ltd. Class H
Jiangxi Rimag Group Co., Ltd. is a leading medical group in China, specializing in medical imaging. It operates a comprehensive medical imaging platform offering diversified services across the medical imaging industry chain, including imaging center services, imaging solution services, and Rimag Cloud services.
Average Trading Volume: 7,847,024
Technical Sentiment Signal: Strong Sell
See more data about 2522 stock on TipRanks’ Stock Analysis page.